GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
NCT02875548 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect82/100
StatusTERMINATED
PhasePHASE1 / PHASE2
Lead sponsorEpizyme, Inc.
Last update2026-10-28
Public-record facts
| Intervention | Tazemetostat (DRUG) |
|---|---|
| Condition | Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL) |
| Enrollment | 58 |
| Why stopped | Sponsor decision; no additional participant enrollment was anticipated. |
| Results posted | Yes |
Why Beacon surfaced it
- The record is terminated and was updated 2026-10-28.
- It is an interventional PHASE1/PHASE2 study with a named drug intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
- ClinicalTrials.gov indicates posted results are available.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT02875548. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.